Implementing a Sodium-Glucose Cotransporter 2 Inhibitor Module With a Software Tool (Future Health Today): Qualitative Study

被引:1
|
作者
Suen, Matthew [1 ]
Manski-Nankervis, Jo -Anne [1 ]
McBride, Caroline [1 ]
Lumsden, Natalie [1 ]
Hunter, Barbara [1 ]
机构
[1] Univ Melbourne, Dept Gen Practice & Primary Care, Level 3,North Wing,Bldg,181 Grattan St,Med Bldg, Parkville 3010, Australia
关键词
type; 2; diabetes; CP-FIT; electronic health; clinical decision support tool; primary care; SGLT2; inhibitor; complication; tool; digital health intervention; thematic analysis; decision support; diabetes management; CLINICAL DECISION-SUPPORT; PRIMARY-CARE; MANAGEMENT;
D O I
10.2196/50737
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Primary care plays a key role in the management of type 2 diabetes. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been demonstrated to reduce hospitalization and cardiac and renal complications. Tools that optimize management, including appropriate prescribing, are a priority for treating chronic diseases. Future Health Today (FHT) is software that facilitates clinical decision support and quality improvement. FHT applies algorithms to data stored in electronic medical records in general practice to identify patients who are at risk of a chronic disease or who have a chronic disease that may benefit from intensification of management. The platform continues to evolve because of rigorous evaluation, continuous improvement, and expansion of the conditions hosted on the platform. FHT currently displays recommendations for the identification and management of chronic kidney disease, cardiovascular disease, type 2 diabetes, and cancer risk. A new module will be introduced to FHT focusing on SGLT2 inhibitors in patients with type 2 diabetes who have chronic kidney diseases, cardiovascular diseases, or risk factors for cardiovascular disease. Objective: The study aims to explore the barriers and enablers to the implementation of an SGLT2 inhibitor module within the Future Health Today software. Methods: Clinic staff were recruited to participate in interviews on their experience in their use of a tool to improve prescribing behavior for SGLT2 inhibitors. Thematic analysis was guided by Clinical Performance Feedback Intervention Theory. Results: In total, 16 interviews were completed. Identified enablers of use included workflow alignment, clinical appropriateness, and active delivery of the module. Key barriers to use were competing priorities, staff engagement, and knowledge of the clinical topic. Conclusions: There is a recognized benefit to the use of a clinical decision support tool to support type 2 diabetes management, but barriers were identified that impeded the usability and actionability of the module. Successful and effective implementation of this tool could support the optimization of patient management of type 2 diabetes in primary care.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] The effect of renal function on the pharmacokinetics and pharmacodynamics of enavogliflozin, a potent and selective sodium-glucose cotransporter-2 inhibitor, in type 2 diabetes
    Jeong, Sae Im
    Ban, Mu Seong
    Hwang, Jun-Gi
    Park, Min-Kyu
    Lim, Soo
    Kim, Sejoong
    Kwon, Soon Kil
    Kim, Yoonjin
    Cho, Jae Min
    Na, Jae Jin
    Huh, Wan
    Chung, Jae-Yong
    DIABETES OBESITY & METABOLISM, 2024, 26 (07) : 2588 - 2597
  • [22] Clinical effect of using a sodium-glucose cotransporter 2 inhibitor in type 2 diabetes mellitus
    Niu, Jiapeng
    Zhao, Lijuan
    Wang, Fei
    Wang, Jing
    Sun, Yanan
    Wang, Fang
    Gao, Yanyan
    Xian, Yuxin
    Li, Li
    Guo, Yunlei
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2020, 13 (12): : 9864 - 9870
  • [23] Effect of sodium-glucose cotransporter 2 inhibitor, empagliflozin, and α-glucosidase inhibitor, voglibose, on hepatic steatosis in an animal model of type 2 diabetes
    Kim, Ji-Won
    Lee, Ye-Jee
    You, Young-Hye
    Moon, Min Kyong
    Yoon, Kun-Ho
    Ahn, Yu-Bae
    Ko, Seung-Hyun
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2019, 120 (05) : 8534 - 8546
  • [24] Safety and Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitor Combined with Medical Nutrition Therapy for Hyperglycemia in Acute Stroke: A Retrospective Study
    Mori, Takahisa
    Yoshioka, Kazuhiro
    Tanno, Yuhei
    Kasakura, Shigen
    METABOLITES, 2022, 12 (01)
  • [25] Emulating a Target Trial Using Primary-Care Electronic Health Records: Sodium-Glucose Cotransporter 2 Inhibitor Medications and Hemoglobin A1c
    Kalia, Sumeet
    Saarela, Olli
    O'Neill, Braden
    Meaney, Christopher
    Moineddin, Rahim
    Sullivan, Frank
    Greiver, Michelle
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2023, 192 (05) : 782 - 789
  • [26] Sodium-Glucose Cotransporter 2 Inhibitor Treatment and Risk of Atrial Fibrillation: Scandinavian Cohort Study
    Engstroem, Arvid
    Wintzell, Viktor
    Melbye, Mads
    Hviid, Anders
    Eliasson, Bjoern
    Gudbjoernsdottir, Soffia
    Hveem, Kristian
    Jonasson, Christian
    Svanstroem, Henrik
    Pasternak, Bjoern
    Ueda, Peter
    DIABETES CARE, 2023, 46 (02) : 351 - 360
  • [27] Severe Vulvovaginal Candidiasis Associated With Sodium-Glucose Cotransporter 2 Inhibitor Use in Postmenopausal Women
    Miao, Vera Y.
    Wijaya, Marlene
    Fischer, Gayle
    Saunderson, Rebecca B.
    JOURNAL OF LOWER GENITAL TRACT DISEASE, 2024, 28 (04) : 371 - 376
  • [28] Sodium-glucose cotransporter 2 inhibitor canagliflozin attenuates lung cancer cell proliferation in vitro
    Yamamoto, Leona
    Yamashita, Shinichi
    Nomiyama, Takashi
    Kawanami, Takako
    Hamaguchi, Yuriko
    Shigeoka, Toru
    Horikawa, Tsuyoshi
    Tanaka, Yuki
    Yanase, Toshihiko
    Kawanami, Daiji
    Iwasaki, Akinori
    DIABETOLOGY INTERNATIONAL, 2021, 12 (04) : 389 - 398
  • [29] Importance of sodium-glucose cotransporter 2 inhibitor use in diabetic patients with acute heart failure
    Kambara, Takahiro
    Shibata, Rei
    Osanai, Hiroyuki
    Nakashima, Yoshihito
    Asano, Hiroshi
    Murohara, Toyoaki
    Ajioka, Masayoshi
    THERAPEUTIC ADVANCES IN CARDIOVASCULAR DISEASE, 2019, 13
  • [30] Haemodynamic Effects of Sodium-Glucose Cotransporter 2 Inhibitor Treatment in Chronic Heart Failure Patients
    Nilsson, C. Noah
    Ersboll, Mads Kristian
    Gustafsson, Finn
    CARDIAC FAILURE REVIEW, 2024, 10